Innoskel is a pioneering platform biotechnology company developing therapies for rare bone diseases. Innoskel's first asset is a treatment option for a group of rare skeletal disorders collectively known as type 2 collagenopathies, the most severe of which with symptoms present from birth is Spondyloepiphyseal Dysplasia congenita (SEDc), the second leading cause of dwarfism worldwide. Innoskel’s lead gene therapy asset for SEDc has demonstrated good efficacy in proof-of-concept studies. The company’s fundamental mission is to improve the lives of patients living with rare bone disorders and to answer their unmet needs, keeping their voices at the heart of all they do.
Company Details
- Employees
- 2
- Founded
- -
- Address
- Sophia Antipolis, Fr
- Industry
- Biotechnology
- Website
- http://www.innoskel.com
- HQ
- Sophia Antipolis
Innoskel Questions
Innoskel's website is http://www.innoskel.com
Innoskel's LinkedIn profile is https://fr.linkedin.com/company/innoskel
Innoskel has
2 employees.
View email and phone details for 2
employees at Innoskel.
Innoskel's industry is
Biotechnology
Innoskel's top competitors are
Nuvisan,
Amkbiotech,
Bionea Lab,
Biper Therapeutics,
Phenocell (Axol Bioscience Ltd.),
Therachon,
Roca Therapeutics,
E-Phy-Science,
Txcell,
Sangamo Therapeutics France.
Innoskel's categories are Biotechnology
Innoskel's founding year is 2020
